Disordered FGF23 and mineral metabolism in children with CKD

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 2, 2014, Pages 344-353

  Portale, Anthony A ^a   Wolf, Myles ^b   Jüppner, Harald ^b   Messinger, Shari ^c   Kumar, Juhi ^d   Wesseling Perry, Katherine ^e   Schwartz, George J ^f   Furth, Susan L ^g   Warady, Bradley A ^h   Salusky, Isidro B ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; AGE FACTORS; BIOLOGICAL MARKERS; CALCIUM; CANADA; CHILD; CHILD, PRESCHOOL; CREATININE; CROSS-SECTIONAL STUDIES; CYSTATIN C; EARLY DIAGNOSIS; FIBROBLAST GROWTH FACTORS; GLOMERULAR FILTRATION RATE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; INFANT; KIDNEY; PARATHYROID HORMONE; PHOSPHORUS; PREDICTIVE VALUE OF TESTS; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX; UNITED STATES; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84893560373     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.05840513     Document Type: Article

References (46)

1. McDonald SP, Craig JC; Australian and New Zealand Paediatric Nephrology Association: Long-term survival of children with end-stage renal disease. N Engl JMed 350: 2654-2662, 2004
2. Pitts TO, Piraino BH, Mitro R, Chen TC, Segre GV, Greenberg A, Puschett JB: Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab 67: 876-881, 1988
3. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 71: 31-38, 2007
4. Portale AA, Booth BE, Tsai HC, Morris RC Jr.: Reduced plasma concentration of 1,25-dihydroxyvitamin D in children with moderate renal insufficiency. Kidney Int 21: 627-632, 1982
5. Bacchetta J, Dubourg L, Harambat J, Ranchin B, Abou-Jaoude P, Arnaud S, Carlier MC, Richard M, Cochat P: The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. J Clin Endocrinol Metab 95: 1741-1748, 2010
6. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H, Wolf M: Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16: 2205-2215, 2005
7. Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79: 1370-1378, 2011
8. 3 production. J Biol Chem 278: 2206-2211, 2003
9. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T: FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19: 429-435, 2004
10. Perwad F, Zhang MY, Tenenhouse HS, Portale AA: Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. AmJ Physiol Renal Physiol 293: F1577-F1583, 2007
11. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, König P, Kraatz G, Mann JF, Müller GA, Köhler H, Riegler P; MMKD Study Group: Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 18: 2600-2608, 2007
12. Lundberg S, Qureshi AR, Olivecrona S, Gunnarsson I, Jacobson SH, Larsson TE: FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy. Clin J Am Soc Nephrol 7: 727-734, 2012
13. Scialla JJ, Astor BC, Isakova T, Xie H, Appel LJ, Wolf M: Mineral metabolites andCKDprogression in AfricanAmericans. J AmSoc Nephrol 24: 125-135, 2013
14. Gutiérrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M: Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119: 2545-2552, 2009
15. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John SuttonM, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro OM, Kusek JW, Keane MG, Wolf M: FGF23 induces left ventricular hypertrophy. J Clin Invest 121: 4393-4408, 2011
16. GutiérrezOM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359: 584-592, 2008
17. Isakova T, Xie H, YangW, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Group: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305: 2432-2439, 2011
18. van Husen M, Fischer AK, Lehnhardt A, Klaassen I, Möller K, Müller-Wiefel DE, Kemper MJ: Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease. Kidney Int 78: 200-206, 2010
19. Siomou E, Challa A, PrintzaN, Giapros V, Petropoulou F, Mitsioni A, Papachristou F, Stefanidis CJ: Serum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease. Pediatr Nephrol 26: 1105-1114, 2011
20. Pereira RC, JuppnerH, Azucena-Serrano CE, YadinO, Salusky IB, Wesseling-Perry K: Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone 45: 1161-1168, 2009
21. Sinha MD, Turner C, Dalton RN, Rasmussen P, Waller S, Booth CJ, Goldsmith DJ: Investigating FGF-23 concentrations and its relationship with declining renal function in paediatric patients with pre-dialysis CKD Stages 3-5. Nephrol Dial Transplant 27: 4361-4368, 2012
22. Wesseling-Perry K, Pereira RC, Tseng CH, Elashoff R, Zaritsky JJ, Yadin O, Sahney S, Gales B, Jüppner H, Salusky IB: Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol 7: 146-152, 2012
23. Furth SL, Cole SR, Moxey-Mims M, Kaskel F, Mak R, Schwartz G, Wong C, Muñoz A, Warady BA: Design and methods of the Chronic Kidney Disease in Children (CKiD) prospective cohort study. Clin J Am Soc Nephrol 1: 1006-1015, 2006
24. Schwartz GJ, Haycock GB, Edelmann CMJr., Spitzer A: A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58: 259-263, 1976
25. Schwartz GJ, Furth S, Cole SR, Warady B, Muñoz A: Glomerular filtration rate via plasma iohexol disappearance: Pilot study for chronic kidney disease in children. Kidney Int 69: 2070-2077, 2006
26. Schwartz GJ, Schneider MF, Maier PS, Moxey-Mims M, Dharnidharka VR, Warady BA, Furth SL, Muñoz A: Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C. Kidney Int 82: 445-453, 2012
27. Fischer DC, Mischek A, Wolf S, Rahn A, Salweski B, Kundt G, Haffner D: Paediatric reference values for the C-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase. Ann Clin Biochem 49: 546-553, 2012
28. Wagner D, Hanwell HE, Vieth R: An evaluation of automated methods for measurement of serum 25-hydroxyvitamin D. Clin Biochem 42: 1549-1556, 2009
29. ErsfeldDL, RaoDS, Body JJ, Sackrison JL Jr., Miller AB, ParikhN, Eskridge TL, Polinske A, Olson GT, MacFarlane GD: Analytical and clinical validation of the 25 OH vitamin D assay for the LIAISON automated analyzer. Clin Biochem 37: 867-874, 2004
30. 125I-labeled tracer. Clin Chem 42: 586-592, 1996
31. Lockitch G, Halstead AC, Wadsworth L, Quigley G, Reston L, Jacobson B: Age-and sex-specific pediatric reference intervals and correlations for zinc, copper, selenium, iron, vitamins A and E, and related proteins. Clin Chem 34: 1625-1628, 1988
32. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42[Suppl 3]: S1-S201, 2003
33. Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F, Fukagawa M: Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 44: 250-256, 2004
34. 2D. Kidney Int 27: 565-573, 1985
35. Hasegawa H, Nagano N, Urakawa I, Yamazaki Y, Iijima K, Fujita T, Yamashita T, Fukumoto S, Shimada T: Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 78: 975-980, 2010
36. Pavik I, Jaeger P, Kistler AD, Poster D, Krauer F, Cavelti-Weder C, Rentsch KM, Wüthrich RP, Serra AL: Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate. Kidney Int 79: 234-240, 2011
37. Shimada T, KakitaniM, YamazakiY, HasegawaH, TakeuchiY, Fujita T, Fukumoto S, Tomizuka K, Yamashita T: Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113: 561-568, 2004
38. Gordon CM, Feldman HA, Sinclair L, Williams AL, Kleinman PK, Perez-Rossello J, Cox JE: Prevalence of vitamin D deficiency among healthy infants and toddlers. Arch Pediatr Adolesc Med 162: 505-512, 2008
39. Kumar J, Muntner P, Kaskel FJ, Hailpern SM, Melamed ML: Prevalence and associations of 25-hydroxyvitamin D deficiency in US children: NHANES 2001-2004. Pediatrics 124: e362-e370, 2009
40. Tuchman S, Kalkwarf HJ, Zemel BS, Shults J, Wetzsteon RJ, Foerster D, Strife CF, Leonard MB: Vitamin D deficiency and parathyroid hormone levels following renal transplantation in children. Pediatr Nephrol 25: 2509-2516, 2010
41. Menon S, Valentini RP, Hidalgo G, Peschansky L, Mattoo TK: Vitamin D insufficiency and hyperparathyroidism in children with chronic kidney disease. Pediatr Nephrol 23: 1831-1836, 2008
42. Hari P, Gupta N, Hari S, Gulati A, Mahajan P, Bagga A: VitaminD insufficiency and effect of cholecalciferol in children with chronic kidney disease. Pediatr Nephrol 25: 2483-2488, 2010
43. Kalkwarf HJ, Denburg MR, Strife CF, Zemel BS, Foerster DL, Wetzsteon RJ, Leonard MB: Vitamin D deficiency is common in children and adolescents with chronic kidney disease. Kidney Int 81: 690-697, 2012
44. Furth SL, Abraham AG, Jerry-Fluker J, Schwartz GJ, Benfield M, Kaskel F, Wong C, Mak RH, Moxey-Mims M, Warady BA: Metabolic abnormalities, cardiovascular disease risk factors, and GFR decline in children with chronic kidney disease. Clin J Am Soc Nephrol 6: 2132-2140, 2011
45. John GB, Cheng CY, Kuro-o M: Role of Klotho in aging, phosphate metabolism, and CKD. Am J Kidney Dis 58: 127-134, 2011
46. Wan M, Smith C, Shah V, Gullet A, Wells D, Rees L, Shroff R: Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease. Nephrol Dial Transplant 28: 153-161, 2013